Evidence map›Paper›PMID 28264026›Full record

ArticlePloS one2017

Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44.

Deborah Wessels, Daniel F Lusche, Edward Voss, Spencer Kuhl, Emma C Buchele, Michael R Klemme, Kanoe B Russell, Joseph Ambrose, Benjamin A Soll, Aaron Bossler and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. CD44 as a tumor biomarker and therapeutic target.Experimental hematology & oncology · 2020
    Review
  8. Article
  9. Article
  10. OverexpressingOncotarget · 2018
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Deborah WesselsDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Daniel F LuscheDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Edward VossDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Spencer KuhlDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Emma C BucheleDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Michael R KlemmeDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Kanoe B RussellDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Joseph AmbroseDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Benjamin A SollDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.
Aaron BosslerDepartment of Molecular Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA United States of America.
Mohammed MilhemDepartment of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA United States of America.
Charles GoldmanMercy Hospital System of Des Moines, Des Moines, IA United States of America.
David R SollDevelopmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA United States of America.ORCID http://orcid.org/0000-0002-5059-0315
University of Iowa · USUniversity of Iowa Hospitals and Clinics · USCHI Health Mercy Council Bluffs · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
RESEARCH TRAINING IN INFECTIOUS DISEASEST32AI007343 · NIAID · UNIVERSITY OF IOWA · PI STAPLETON, JACK T. · 1988 to 2024
$5.0M
NIAID NIH HHS T32 AI007343
6 · The paper itself

Abstract

Using unique computer-assisted 3D reconstruction software, it was previously demonstrated that tumorigenic cell lines derived from breast tumors, when seeded in a 3D Matrigel model, grew as clonal aggregates which, after approximately 100 hours, underwent coalescence mediated by specialized cells, eventually forming a highly structured large spheroid. Non-tumorigenic cells did not undergo coalescence. Because histological sections of melanomas forming in patients suggest that melanoma cells migrate and coalesce to form tumors, we tested whether they also underwent coalescence in a 3D Matrigel model. Melanoma cells exiting fragments of three independent melanomas or from secondary cultures derived from them, and cells from the melanoma line HTB-66, all underwent coalescence mediated by specialized cells in the 3D model. Normal melanocytes did not. However, coalescence of melanoma cells differed from that of breast-derived tumorigenic cell lines in that they 1) coalesced immediately, 2) underwent coalescence as individual cells as well as aggregates, 3) underwent coalescence far faster and 4) ultimately formed long, flat, fenestrated aggregates that were extremely dynamic. A screen of 51 purified monoclonal antibodies (mAbs) targeting cell surface-associated molecules revealed that two mAbs, anti-beta 1 integrin/(CD29) and anti-CD44, blocked melanoma cell coalescence. They also blocked coalescence of tumorigenic cells derived from a breast tumor. These results add weight to the commonality of coalescence as a characteristic of tumorigenic cells, as well as the usefulness of the 3D Matrigel model and software for both investigating the mechanisms regulating tumorigenesis and screening for potential anti-tumorigenesis mAbs.

Indexed as

Antibodies, MonoclonalBiomarkersCell AdhesionCell LineCell TrackingCollagenDrug CombinationsHumansHyaluronan ReceptorsIntegrin beta1LamininMelanocytesMelanomaPhenotypeProteoglycansSpheroids, CellularAntibodies, MonoclonalBiomarkersCollagenDrug CombinationsHyaluronan ReceptorsIntegrin beta1LamininmatrigelProteoglycans

Identifiers

PMID28264026
PMCPMC5338862
OpenAlexW2594539021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.